Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Placebo-controlled, Double-blind, Parallel-group Phase 2a Exploratory Study With Placebo run-in to Investigate PK/PD Effects, Safety, Tolerability and Pharmacokinetics of REM0046127 Oral Suspension Compared With Placebo in Subjects With Mild to Moderate Alzheimer's Disease

NCT05478031 is registered in ClinicalTrials.gov with reMYND as lead sponsor.

NCT NCT05478031
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05478031 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Placebo-controlled, Double-blind, Parallel-group Phase 2a Exploratory Study With Placebo run-in to Investigate PK/PD Effects, Safety, Tolerability and Pharmacokinetics of REM0046127 Oral Suspension Compared With Placebo in Subjects With Mild to Moderate Alzheimer's Disease
Lead sponsor
reMYND
Phase
Phase 2
Overall status
Terminated
Start date
June 7, 2022
Completion date
June 4, 2024
Enrollment
14 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer disease